Receptor-level blockade offers broader coverage: anifrolumab (anti-IFNAR1) inhibits signaling downstream of both IFN-α and IFN-β, suppresses ISGs, and confers multidomain clinical improvement in SLE, leading to regulatory approval [19,169,266,388]. Here, IFNA2 is linked to systemic lupus erythematosus.